A5042297363- CAR-T cell therapy research
- Monoclonal and Polyclonal Antibodies Research
- Immune Cell Function and Interaction
- Biosimilars and Bioanalytical Methods
- Chronic Lymphocytic Leukemia Research
- Phagocytosis and Immune Regulation
- Acute Myeloid Leukemia Research
- HIV/AIDS drug development and treatment
- Adenosine and Purinergic Signaling
- Chronic Myeloid Leukemia Treatments
QIMR Berghofer Medical Research Institute
2022-2024
T-cell-engaging bispecific antibody (T-BsAb, also known as BiTE) therapy has emerged a powerful therapeutic modality against multiple myeloma. Given that T-BsAb redirects endogenous T cells to eliminate tumor cells, reinvigorating dysfunctional may be potential approach improve the efficacy of T-BsAb. While various immunostimulatory cytokines can potentiate effector T-cell functions, optimal cytokine treatment for is yet established, partly due concern release syndrome driven by aberrant...
T-cell-engaging bispecific antibodies (T-BsAb) have produced impressive clinical responses in patients with relapsed/refractory B-cell malignancies, although treatment failure remains a major challenge. Growing evidence suggests that complex interplay between immune cells and tumor is implicated the mechanism of action therefore, understanding regulatory mechanisms might provide clue for how to improve efficacy T-BsAb therapy. Here, we investigated functional impact T (Treg) on anti-tumor...